Cargando…
A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
Alzheimer’s disease (AD), a progressive neurodegenerative disease, is characterized by the accumulation of senile plaques, neurofibrillary tangles, and loss of synapses and neurons in the brain. The pathophysiological process of AD begins with a long asymptomatic phase, which provides a potential op...
Autores principales: | Zhong, Xiaofang, Wang, Jingxin, Carlsson, Cynthia, Okonkwo, Ozioma, Zetterberg, Henrik, Li, Lingjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330998/ https://www.ncbi.nlm.nih.gov/pubmed/30666187 http://dx.doi.org/10.3389/fnmol.2018.00483 |
Ejemplares similares
-
Comparative Evaluation of MS-based Metabolomics Software and Its Application to Preclinical Alzheimer’s Disease
por: Hao, Ling, et al.
Publicado: (2018) -
In-depth Site-specific Analysis of N-glycoproteome in Human Cerebrospinal Fluid and Glycosylation Landscape Changes in Alzheimer's Disease
por: Chen, Zhengwei, et al.
Publicado: (2021) -
Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015) -
Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021) -
Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)